Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR01382
|
|||||
| Drug Name |
Alfuzosin
|
|||||
| Synonyms |
Alfusosine; Alfuzosina; Alfuzosine; Alfuzosinum; Alphuzosine; Alfuzosina [Spanish]; Alfuzosine [French]; Alfuzosinum [Latin]; Alfuzosin (INN); Alfuzosin [INN:BAN]; Xatral (TN); N-[3-[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]propyl]oxolane-2-carboxamide; N-(3-((4-Amino-6,7-dimethoxy-2-quinazolinyl)methylamino)propyl)tetrahydro-2-furancarboxamide; N-{3-[(4-amino-6,7-dimethoxyquinazolin-2-yl)(methyl)amino]propyl}tetrahydrofuran-2-carboxamide
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Benign prostatic hyperplasia [ICD11: GA90] | Approved | [1] | |||
| Therapeutic Class |
Antihypertensive Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C19H27N5O4
|
|||||
| Canonical SMILES |
CN(CCCNC(=O)C1CCCO1)C2=NC3=CC(=C(C=C3C(=N2)N)OC)OC
|
|||||
| InChI |
InChI=1S/C19H27N5O4/c1-24(8-5-7-21-18(25)14-6-4-9-28-14)19-22-13-11-16(27-3)15(26-2)10-12(13)17(20)23-19/h10-11,14H,4-9H2,1-3H3,(H,21,25)(H2,20,22,23)
|
|||||
| InChIKey |
WNMJYKCGWZFFKR-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 81403-80-7
|
|||||
| Pharmaceutical Properties | Molecular Weight | 389.4 | Topological Polar Surface Area | 112 | ||
| Heavy Atom Count | 28 | Rotatable Bond Count | 8 | |||
| Hydrogen Bond Donor Count | 2 | Hydrogen Bond Acceptor Count | 8 | |||
| XLogP |
1.7
|
|||||
| PubChem CID | ||||||
| PubChem SID |
7348779
, 7978547
, 8151421
, 11371965
, 11374754
, 11466350
, 11467470
, 11484165
, 11485980
, 11488321
, 11490878
, 11493022
, 14805133
, 26612860
, 26680540
, 26719847
, 26749009
, 26749010
, 29221272
, 46386655
, 46508512
, 47509539
, 47656603
, 47730752
, 47879632
, 48029201
, 48328565
, 49681674
, 49699344
, 49971151
, 50107503
, 50107504
, 50315525
, 51091463
, 56464294
, 57321133
, 81092780
, 85209969
, 85788468
, 85789670
, 90341616
, 92124875
, 92308116
, 92308400
, 103194715
, 103941451
, 104299580
, 117887447
, 124637420
, 124658863
|
|||||
| ChEBI ID |
ChEBI:51141
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | BCRP | Transporter Info | Breast cancer resistance protein | Substrate | [2] | |
| References | ||||||
| 1 | Alfuzosin was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | In vitro and in vivo evidence for the importance of breast cancer resistance protein transporters (BCRP/MXR/ABCP/ABCG2). Handb Exp Pharmacol. 2011;(201):325-71. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.